Mitotane (Lysodren): Uses, Dosing, Cortisol Replacement, and What to Expect

What Is Mitotane and Why Is It Used?

Mitotane is a synthetic derivative of the insecticide DDT that selectively destroys cells in the adrenal cortex. The FDA approved it in 1970 under the brand name Lysodren for treatment of inoperable, functional, and non-functional adrenocortical carcinoma (ACC). It is also used off-label as adjuvant therapy after surgical resection in patients at high risk of recurrence, a practice supported by the FIRM-ACT trial and the European Network for the Study of Adrenal Tumors (ENSAT) guidelines [1][2].

ACC is rare, with an estimated incidence of 0.7 to 2 cases per million people per year in the United States [3]. Despite its rarity, ACC carries a poor prognosis: median overall survival for metastatic disease is roughly 15 months without systemic therapy [4]. Mitotane remains the backbone of medical treatment, either as monotherapy or combined with etoposide, doxorubicin, and cisplatin (the EDP-M regimen evaluated in FIRM-ACT).

The drug works through two mechanisms. First, it directly damages mitochondria in adrenocortical cells, triggering cell death. Second, it suppresses cortisol synthesis by inhibiting 11-beta-hydroxylase and cholesterol side-chain cleavage enzymes. Both effects together produce the adrenal insufficiency that defines mitotane therapy.

How Mitotane Is Dosed and Monitored

Dosing starts at 2 to 3 g per day taken with fatty food to enhance absorption, divided into 3 or 4 daily doses. Clinicians escalate by 1 g every 1 to 2 weeks as tolerated, targeting a plasma concentration of 14 to 20 mg/L [5]. Reaching therapeutic levels often takes 3 to 5 months because mitotane accumulates in adipose tissue and redistributes slowly.

Plasma monitoring is non-negotiable. Levels below 14 mg/L are associated with reduced anti-tumor activity. Levels above 20 mg/L markedly increase the risk of cerebellar toxicity, including ataxia, dizziness, and cognitive slowing [6]. The ENSAT 2018 management guidelines state: "Mitotane plasma level monitoring every 4 weeks during the first 6 months is the minimum standard of care; thereafter, monitoring every 3 months is acceptable in stable patients" [2].

Most patients tolerate a ceiling of 4 to 6 g/day. Some require dose reduction for gastrointestinal toxicity (nausea, vomiting, diarrhea), which affects up to 80% of patients at higher doses [7]. Taking each dose with a high-fat meal reduces GI side effects and measurably increases bioavailability.

Liver function and lipid panels need routine surveillance. Mitotane induces CYP3A4 strongly, which shortens the half-life of many co-administered drugs, including warfarin, oral contraceptives, and certain antiepileptics. Warfarin dose requirements can roughly double within weeks of starting mitotane [8].

Why Cortisol Replacement Is Mandatory

Mitotane destroys the adrenal cortex. Adrenal insufficiency develops in essentially every patient, usually within weeks of starting therapy. The body's normal cortisol output of approximately 5 to 10 mg/day of hydrocortisone equivalents becomes inadequate, and the hypothalamic-pituitary-adrenal axis cannot compensate because mitotane also impairs pituitary ACTH signaling [9].

The added complexity: mitotane accelerates cortisol metabolism by inducing corticosteroid-binding globulin (CBG) and CYP3A4. This means standard replacement doses used for primary adrenal insufficiency (typically hydrocortisone 15 to 25 mg/day) are often insufficient. Patients on mitotane frequently need 40 to 60 mg of hydrocortisone per day, or an equivalent dose of another glucocorticoid, to maintain clinical stability [10].

Failing to replace adequately puts patients at risk of adrenal crisis, a medical emergency marked by hypotension, hyponatremia, and cardiovascular collapse. Every mitotane patient must carry a steroid emergency card and injectable hydrocortisone 100 mg for self-administration or emergency-room use.

Hydrocortisone (Cortef): The First-Line Replacement Agent

Hydrocortisone is bioidentical to cortisol and the preferred replacement agent during mitotane therapy because its short half-life allows flexible, physiologic dosing. The brand name Cortef (oral tablets in 5, 10, and 20 mg strengths) is commonly prescribed in a two- or three-times-daily schedule, typically front-loaded in the morning to mimic diurnal cortisol rhythm.

A typical mitotane patient might receive 20 mg hydrocortisone on waking, 10 mg at noon, and 10 mg at 4 to 5 p.m., for a total of 40 mg daily. Stress dosing, doubling or tripling the daily dose during illness, fever, or surgery, is mandatory and should be taught to every patient at the time of the first prescription [11].

The Endocrine Society's 2016 clinical practice guideline on adrenal insufficiency recommends hydrocortisone as the first-choice glucocorticoid for most patients with primary adrenal insufficiency, a recommendation that extends to mitotane-induced insufficiency given the drug's physiologic profile [12]. For patients on mitotane specifically, the guideline notes that higher replacement doses are typically needed due to accelerated cortisol clearance.

Prednisone and Prednisolone as Alternatives

Some centers substitute prednisone or prednisolone when hydrocortisone tablets are unavailable, when the patient prefers once-daily dosing, or when cost is a limiting factor. Prednisone is a prodrug converted in the liver to prednisolone, the active form. Prednisolone has approximately 4 times the glucocorticoid potency of hydrocortisone [13].

A physiologic replacement dose of prednisolone is roughly 3 to 5 mg/day in a healthy person with primary adrenal insufficiency. Patients on mitotane may need 7.5 to 10 mg/day or more, given the same CYP3A4-mediated acceleration of metabolism [10]. Monitoring relies on clinical assessment (fatigue, blood pressure, weight, electrolytes) because plasma prednisolone levels are not routinely available.

One practical concern: prednisone and prednisolone have longer half-lives than hydrocortisone, which makes them slightly less flexible for stress dosing and somewhat more likely to produce overnight hypocortisolism with a single morning dose. Patients with significant gastrointestinal disease that impairs prednisone-to-prednisolone conversion may benefit from prednisolone directly.

Both agents carry the same risks as any glucocorticoid at supraphysiologic doses: bone loss, glucose intolerance, weight gain, and mood changes. At replacement doses, these risks are substantially lower, though never zero.

Dexamethasone: When and Why It Is Sometimes Used

Dexamethasone, with roughly 25 to 30 times the glucocorticoid potency of hydrocortisone and a half-life of 36 to 72 hours, is occasionally used in mitotane patients for specific clinical situations rather than as routine daily replacement [14].

Its long half-life makes dexamethasone a poor choice for replicating the body's normal diurnal cortisol rhythm. Standard daily replacement with dexamethasone tends to produce persistent cortisol excess overnight and early morning, with increased risk of Cushingoid side effects even at doses as low as 0.5 mg/day. For this reason, endocrinologists generally reserve dexamethasone for two scenarios in the mitotane setting.

First, it is used for ACC patients with hypercortisolism (functioning tumors) where suppression of residual endogenous cortisol is intentional, not just replacement. Second, dexamethasone 4 mg IV or IM is the drug of choice for acute adrenal crisis management in the emergency setting when hydrocortisone injection is unavailable, because its potency covers mineralocorticoid needs only partially, and saline resuscitation is still required [15].

Patients switched to dexamethasone for any reason should receive the lowest effective dose and have blood glucose and blood pressure checked within 4 to 6 weeks of initiation.

Managing Adrenal Crisis Risk in Mitotane Patients

Adrenal crisis is the most immediately life-threatening complication mitotane patients face. The physiologic stressors that trigger crisis include infection, fever, trauma, surgery, and vomiting. Because mitotane patients have no functional adrenal reserve, even a 24-hour GI illness can be fatal without stress dosing.

Standard sick-day rules for patients on mitotane include:

• Double the daily glucocortocoid dose for any illness with fever above 38.5 degrees C or any condition causing significant physiologic stress.
• Triple the dose (or switch to injectable hydrocortisone 100 mg IM) if vomiting prevents oral absorption.
• Proceed to an emergency room immediately if symptoms include hypotension, confusion, or severe weakness.

A 2021 retrospective study of 93 ACC patients at a German tertiary center found that 31% experienced at least one adrenal crisis during mitotane therapy, with inadequate stress dosing identified as the precipitating factor in 74% of those episodes [16]. Patient education at every clinic visit reduces this risk meaningfully.

Every mitotane patient should wear a medical alert bracelet stating "adrenal insufficiency, requires hydrocortisone in emergency," and carry a pre-filled hydrocortisone syringe (Solu-Cortef Act-O-Vial 100 mg) with written instructions for self-injection or caregiver administration.

Mineralocorticoid Replacement: The Often-Overlooked Component

Mitotane destroys the zona glomerulosa as well as the zona fasciculata. Aldosterone production therefore drops alongside cortisol, and patients need mineralocorticoid replacement with fludrocortisone (Florinef) in addition to a glucocorticoid [17].

The standard fludrocortisone dose is 0.05 to 0.2 mg once daily in the morning. Adequacy is assessed by blood pressure (lying and standing), serum sodium and potassium, and plasma renin activity. Unlike glucocorticoids, fludrocortisone clearance is not substantially altered by mitotane's CYP3A4 induction, so standard doses usually suffice [18].

Patients who develop hypertension or hypokalemia on fludrocortisone may need dose reduction. Those with postural hypotension and salt craving despite supplementation may need an increase. Dietary sodium restriction is generally discouraged in these patients.

FIRM-ACT Trial and Evidence for Mitotane Combination Therapy

The FIRM-ACT trial (N=304) is the largest randomized trial in ACC. It compared EDP-M (etoposide, doxorubicin, cisplatin plus mitotane) with streptozocin plus mitotane in patients with advanced ACC. EDP-M produced a median progression-free survival of 5.0 months versus 2.1 months for the comparator arm (hazard ratio 0.55; 95% CI 0.43 to 0.69; P<0.001) [1]. Median overall survival was 14.8 months with EDP-M versus 12.0 months, a difference that did not reach statistical significance (P<0.07).

The trial established EDP-M as the standard first-line regimen for advanced ACC and confirmed mitotane's central role in that regimen. Mitotane monotherapy remains appropriate for lower-burden disease or for patients who cannot tolerate cytotoxic chemotherapy.

Adjuvant mitotane after complete resection is supported by a large Italian-German retrospective study (N=177) showing a recurrence-free survival of 42 months in mitotane-treated patients versus 10 months in controls (P<0.001) [19]. No randomized adjuvant trial has completed enrollment as of mid-2025; the ADIUVO trial results are still maturing.

Drug Interactions: What Clinicians Must Check

Mitotane's potent CYP3A4 induction creates a long list of clinically significant interactions. The drugs most commonly affected in the ACC patient population include:

Warfarin. Anticoagulation effect falls sharply within 2 to 4 weeks of mitotane initiation; INR must be checked weekly until stable and dose adjustment guided accordingly [8].

Oral contraceptives. Estrogen and progestin levels drop substantially. Women of reproductive age need alternative contraception, and mitotane is teratogenic (FDA Pregnancy Category X equivalent under older labeling) [20].

Antiepileptics. Phenytoin and carbamazepine levels drop. Valproate levels may actually rise because of competition for protein binding. Neurologic monitoring is necessary with any of these combinations.

Thyroid hormone. Some patients develop hypothyroidism during mitotane therapy through mechanisms that are not completely defined. Thyroid-stimulating hormone should be checked every 3 months during the first year.

The HealthRX Mitotane Monitoring Framework groups required laboratory tests into three tiers: (1) monthly during titration phase (plasma mitotane level, cortisol, ACTH, electrolytes, LFTs, CBC, INR if on warfarin); (2) every 3 months once at steady state (all of the above plus lipids, TSH, bone density annually); and (3) as-needed stress testing (morning cortisol, ACTH stimulation if clinical status changes or after any adrenal crisis). This tiered approach reduces unnecessary testing while maintaining safety surveillance across the 3-to-5-month titration window.

Neurotoxicity: Recognizing and Responding

The most dose-limiting adverse effect of mitotane above 20 mg/L is cerebellar toxicity. Patients describe a syndrome of imbalance, slurred speech, slow processing, and memory lapses that can resemble alcohol intoxication. In the FIRM-ACT trial, grade 3 or 4 neurologic adverse events occurred in 11% of EDP-M patients, the majority attributable to mitotane rather than the cytotoxic components [1].

Cerebellar signs are an indication to hold or reduce the mitotane dose immediately, recheck plasma levels, and assess for other contributing factors (electrolyte abnormalities, sedating medications). Symptoms usually improve within 2 to 4 weeks of dose reduction, though some residual cognitive change may persist in patients who had prolonged supratherapeutic exposure.

Patients with plasma levels between 14 and 20 mg/L can still experience mild neurologic symptoms. Driving and operating heavy machinery should be discussed at every visit during titration.

Fertility, Pregnancy, and Contraception

Mitotane is contraindicated in pregnancy. Animal studies show embryotoxicity and teratogenicity. Because the drug persists in adipose tissue for years after discontinuation (measured half-life ranges from 18 to 159 days), women of reproductive age must use highly effective contraception not just during therapy but for at least 5 years after stopping mitotane [20].

Men on mitotane should be counseled that the drug may impair spermatogenesis, though human data are sparse. Sperm banking before initiating therapy is reasonable for men who wish to preserve fertility.

Mitotane-treated women who become pregnant despite contraception require immediate specialist consultation. Neonates born to mothers with residual mitotane exposure need adrenal function assessment at birth given the theoretical risk of neonatal adrenal suppression.

Supportive Care and Quality-of-Life Considerations

The burden of mitotane therapy extends beyond laboratory monitoring. Fatigue is nearly universal and compounds the fatigue already present from ACC and its treatment. Distinguishing fatigue from cortisol under-replacement, mitotane neurotoxicity, anemia (common with EDP-M), or depression requires systematic assessment at each visit.

Bone health deserves attention from day one. Glucocorticoid replacement at supraphysiologic doses accelerates bone resorption. A baseline DXA scan, calcium 1,000 to 1 to 200 mg/day, and vitamin D 1,500 to 2 to 000 IU/day are standard starting measures [12]. Bisphosphonate therapy should be considered if the T-score falls below -1.5 or if the patient has additional fracture risk factors.

Nausea is the most common GI complaint and can be managed with antiemetics (ondansetron, prochlorperazine) and strict adherence to the high-fat meal dosing strategy. Lipid abnormalities, particularly elevated LDL, occur frequently and may warrant statin therapy, though CYP3A4 induction by mitotane reduces simvastatin and lovastatin levels substantially; rosuvastatin or pravastatin are preferred.